These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25257562)

  • 1. Growth hormone treatment for osteoporosis in patients with scoliosis of Prader-Willi syndrome.
    Nakamura Y; Murakami N; Iida T; Asano S; Ozeki S; Nagai T
    J Orthop Sci; 2014 Nov; 19(6):877-82. PubMed ID: 25257562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS
    Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.
    Jørgensen AP; Ueland T; Sode-Carlsen R; Schreiner T; Rabben KF; Farholt S; Høybye C; Christiansen JS; Bollerslev J
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E753-60. PubMed ID: 23436915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
    Fillion M; Deal C; Van Vliet G
    J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The characteristics of scoliosis in Prader-Willi syndrome (PWS): analysis of 58 scoliosis patients with PWS.
    Nakamura Y; Murakami N; Iida T; Ozeki S; Asano S; Nohara Y; Nagai T
    J Orthop Sci; 2015 Jan; 20(1):17-22. PubMed ID: 25253244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological aspects of scoliosis in a cohort of Japanese patients with Prader-Willi syndrome.
    Nakamura Y; Nagai T; Iida T; Ozeki S; Nohara Y
    Spine J; 2009 Oct; 9(10):809-16. PubMed ID: 19665940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone therapy and scoliosis in patients with Prader-Willi syndrome.
    Nagai T; Obata K; Ogata T; Murakami N; Katada Y; Yoshino A; Sakazume S; Tomita Y; Sakuta R; Niikawa N
    Am J Med Genet A; 2006 Aug; 140(15):1623-7. PubMed ID: 16770808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone receptor (GHR) gene polymorphism and scoliosis in Prader-Willi syndrome.
    Butler MG; Hossain W; Hassan M; Manzardo AM
    Growth Horm IGF Res; 2018 Apr; 39():29-33. PubMed ID: 29273483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids.
    Longhi S; Grugni G; Gatti D; Spinozzi E; Sartorio A; Adami S; Fanolla A; Radetti G
    Calcif Tissue Int; 2015 Feb; 96(2):160-6. PubMed ID: 25577526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone treatment and bone mineral density in pediatric patients with Prader-Willi syndrome.
    Oto Y; Murakami N; Inoue T; Matsubara K; Saima S; Ogata H; Ihara H; Nagai T; Matsubara T
    J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1181-1184. PubMed ID: 34162033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Health in Adults With Prader-Willi Syndrome: Clinical Recommendations Based on a Multicenter Cohort Study.
    van Abswoude DH; Pellikaan K; Rosenberg AGW; Davidse K; Coupaye M; Høybye C; Markovic TP; Grugni G; Crinò A; Caixàs A; Poitou C; Mosbah H; Weir T; van Vlimmeren LA; Rutges JPHJ; De Klerk LWL; Zillikens MC; van der Lely AJ; de Graaff LCG
    J Clin Endocrinol Metab; 2022 Dec; 108(1):59-84. PubMed ID: 36149817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.
    Saggese G; Baroncelli GI; Bertelloni S; Barsanti S
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3077-83. PubMed ID: 8768878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.